BALPHARMA.NSBALPHARMA.NSNSE
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+59.0%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+59.0%/yr
vs -33.2%/yr prior
Acceleration
+92.2pp
Accelerating
Percentile
P92
Near historical high
vs 3Y Ago
4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 82.55% |
| Q3 2025 | -2.27% |
| Q2 2025 | -35.17% |
| Q1 2025 | 7.63% |
| Q4 2024 | -2.80% |
| Q3 2024 | 29.27% |
| Q2 2024 | -45.71% |
| Q1 2024 | 53.92% |
| Q4 2023 | -10.86% |
| Q3 2023 | 4.90% |
| Q2 2023 | -17.52% |
| Q1 2023 | 50.45% |
| Q4 2022 | 20.55% |
| Q3 2022 | 23.00% |
| Q2 2022 | 173.89% |
| Q1 2022 | -74.40% |
| Q4 2021 | -4.31% |
| Q3 2021 | -20.94% |
| Q2 2021 | 4.61% |
| Q1 2021 | 29.81% |
| Q4 2020 | -20.88% |
| Q3 2020 | 53.89% |
| Q2 2020 | 220.80% |
| Q1 2020 | -270.74% |
| Q4 2019 | -248.66% |
| Q3 2019 | 76.28% |
| Q2 2019 | -93.39% |
| Q1 2019 | 70.31% |
| Q4 2018 | -18.48% |
| Q3 2018 | 22.67% |
| Q2 2018 | -35.77% |
| Q1 2018 | 19.67% |
| Q4 2017 | 18.87% |
| Q3 2017 | 77.26% |
| Q2 2017 | -14.17% |
| Q1 2017 | -24.34% |
| Q4 2016 | -45.10% |
| Q3 2016 | 61.49% |
| Q2 2016 | 1542.62% |
| Q1 2016 | -104.78% |